As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of AbCellera Biologics Inc. The largest reported stake is Baker Bros. Advisors LP's, at 10.8%. One filing is on record since May 7, 2026 (Schedule 13G/A, May 7, 2026).
Sell to companies like AbCellera Biologics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Baker Bros. Advisors LP · Sole voting: 33,012,138 · Shared voting: 0 · Sole dispositive: 33,012,138 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-05-07
- · Reporting person: Baker Bros. Advisors (GP) LLC · Sole voting: 33,012,138 · Shared voting: 0 · Sole dispositive: 33,012,138 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-05-07
- · Reporting person: Julian C. Baker · Sole voting: 33,012,138 · Shared voting: 0 · Sole dispositive: 33,012,138 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-05-07
- · Reporting person: Felix J. Baker · Sole voting: 33,012,138 · Shared voting: 0 · Sole dispositive: 33,012,138 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-05-07
- · Holder: Baker Bros. Advisors LP · Percent: 10.8% · SCHEDULE 13G/A
AbCellera Biologics Inc. has 1 Schedule 13D or 13G filing on record since 2026-05-07. 1 holder's latest filing reports 5% or more of common shares, no par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 10.8% | 33,012,138 | SCHEDULE 13G/A, 2026-05-07 | 2026-04-30 |
Holding shares or following this stake? See who's behind AbCellera Biologics Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on AbCellera Biologics Inc. and the records around it.
AbCellera Biologics Inc. elsewhere on the record
- Leadership changes Jul 2026
Companies that share a holder
- Baker Bros. Advisors LP also filed stake reports on 25 other companies: Madrigal Pharmaceuticals, Inc. (Nov 2026), Kodiak Sciences Inc. (Sep 2026), BeOne Medicines Ltd. (Sep 2026)
Watch AbCellera Biologics Inc.
Get an email when AbCellera Biologics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on AbCellera Biologics Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on AbCellera Biologics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on AbCellera Biologics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
3 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 33,012,138 | 0 | 33,012,138 | 0 | SCHEDULE 13G/A, 2026-05-07 |
| Baker Bros. Advisors (GP) LLC | 33,012,138 | 0 | 33,012,138 | 0 | SCHEDULE 13G/A, 2026-05-07 |
| Julian C. Baker | 33,012,138 | 0 | 33,012,138 | 0 | SCHEDULE 13G/A, 2026-05-07 |
| Felix J. Baker | 33,012,138 | 0 | 33,012,138 | 0 | SCHEDULE 13G/A, 2026-05-07 |
The latest filing identifies AbCellera Biologics Inc. by CUSIP 00288U106 and gives its principal executive office as 150 W 4th Avenue, Vancouver (SCHEDULE 13G/A, 2026-05-07).
What the percentages are based on
The Funds beneficially own 33,012,138 shares of Common Stock, including 30,275,938 shares of Common Stock directly held by the Funds and 2,736,200 shares issuable upon the exercise of 27,362 EUR Call Options exercisable within 60 days or 10.8% of the outstanding Common Stock. 667 beneficially owns 0.8% and Life Sciences beneficially owns 10.0% of the outstanding Common Stock.Baker Bros. Advisors LP, SCHEDULE 13G/A, 2026-05-07
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-05-07 | Baker Bros. Advisors LP | 10.8% | SCHEDULE 13G/A |
Also on the record for AbCellera Biologics Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 6, 2026 | Leadership change: Lynn Seely appointed, Director | — | Leadership changes | Source |
| June 5, 2026 | Leadership change: Victor Sandor appointed, Director | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for AbCellera Biologics Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.